Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | FGB | P02675 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514428 | 0.91 | L3MBTL1 (0.83) | L3MBTL1MEN1KMT2AALDH1A1NR3C1 | |
| SCHEMBL15758883 | 0.84 | L3MBTL1 (0.72) | L3MBTL1MEN1KMT2AALDH1A1NR3C1 | |
| SCHEMBL5960090 | 0.84 | L3MBTL1 (0.72) | L3MBTL1MEN1KMT2AALDH1A1NR3C1 | |
| SCHEMBL21569861 | 0.83 | L3MBTL1 (0.71) | L3MBTL1MEN1KMT2ANR3C1HTT | |
| SCHEMBL29259788 | 0.82 | L3MBTL1 (0.70) | L3MBTL1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL5562243 | 0.81 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2AHTTFABP4 | |
| SCHEMBL4516684 | 0.80 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2AALDH1A1NR3C1 | |
| SCHEMBL21569713 | 0.80 | L3MBTL1 (0.66) | L3MBTL1MEN1KMT2ANR3C1HTT | |
| SCHEMBL21550426 | 0.80 | L3MBTL1 (0.66) | L3MBTL1MEN1KMT2AALDH1A1NR3C1 | |
| SCHEMBL21569859 | 0.80 | L3MBTL1 (0.66) | L3MBTL1MEN1KMT2ANR3C1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | claimed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | claimed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | claimed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | disclosed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | CYBB, NOX4, NOX1 | L3MBTL1 4483/4885MEN1 3350/4885KMT2A 3543/4885 |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | CYBB, NOX4, NOX1 | L3MBTL1 4483/4885MEN1 3350/4885KMT2A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.